Published in Int J Endocrinol on May 12, 2014
Adrenal disorders and the paediatric brain: pathophysiological considerations and clinical implications. Int J Endocrinol (2014) 0.78
A rare case of juvenile hypertension: coexistence of type 2 multiple endocrine neoplasia -related bilateral pheochromocytoma and reninoma in a young patient with ACE gene polymorphism. BMC Endocr Disord (2015) 0.77
Preliminary experience of the robot-assisted laparoscopic excision of a retroperitoneal mass: A case report. Oncol Lett (2014) 0.76
Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Front Endocrinol (Lausanne) (2015) 0.76
Primary Pulmonary Paraganglioma: A Case Report and Review of Literature. Medicine (Baltimore) (2015) 0.75
Multiple Components of the VHL Tumor Suppressor Complex Are Frequently Affected by DNA Copy Number Loss in Pheochromocytoma. Int J Endocrinol (2014) 0.75
From arterial hypertension complications to von Hippel-Lindau syndrome diagnosis. Ital J Pediatr (2015) 0.75
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 13.49
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (1990) 8.91
Phaeochromocytoma. Lancet (2005) 8.73
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol (1988) 8.61
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
von Hippel-Lindau disease. Lancet (2003) 6.20
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet (2000) 4.55
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria. Cell (1994) 4.17
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet (2005) 4.12
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer (2005) 3.85
SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science (2009) 3.72
Von Hippel-Lindau disease: a genetic study. J Med Genet (1991) 3.61
Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell (2001) 3.49
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab (2001) 3.19
SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet (2010) 3.07
Neurofibromatosis type 1 revisited. Pediatrics (2009) 3.06
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat (1995) 2.91
Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst (2008) 2.89
Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer (1997) 2.86
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 2.83
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet (2001) 2.79
Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat (2010) 2.75
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med (1993) 2.61
PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med (2008) 2.56
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet (2001) 2.56
Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol (2002) 2.51
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Paragangliomas of the head and neck. Oral Oncol (2004) 2.47
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol (2010) 2.42
Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2007) 2.41
Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet (2002) 2.33
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol (1996) 2.32
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet (2010) 2.23
The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab (2009) 2.22
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet (1994) 2.14
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab (2010) 2.09
Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene (2007) 1.97
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92
Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab (2002) 1.84
Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet (1996) 1.83
Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet (1996) 1.76
Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab (2013) 1.69
Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res (2004) 1.68
Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol (2011) 1.66
Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery (2007) 1.64
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer (2013) 1.63
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2013) 1.61
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet (2000) 1.61
Hereditary paraganglioma targets diverse paraganglia. J Med Genet (2002) 1.57
Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol (2010) 1.56
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery (2008) 1.50
Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2009) 1.48
SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med (2009) 1.47
The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens (1994) 1.46
Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin Endocrinol (Oxf) (2013) 1.46
Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol (1995) 1.44
SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab (2011) 1.42
Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) (2006) 1.41
Secondary hypertension in a blood pressure clinic. Arch Intern Med (1987) 1.41
The genetic aspects of neurofibromatosis. Ann N Y Acad Sci (1986) 1.38
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38
Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet (2000) 1.33
Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) (2008) 1.32
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene (2004) 1.32
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol (2013) 1.32
Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab (2006) 1.31
A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet (2008) 1.26
Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer (2005) 1.23
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA (2010) 1.22
Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab (2008) 1.22
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res (2011) 1.22
[Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)]. Nouv Presse Med (1981) 1.22
Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med (1995) 1.17
Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med (2006) 1.16